These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Short-term intraocular pressure trends after intravitreal injection of bevacizumab (avastin).
    Author: Mazzulla DA, Hariprasad SM, Jager RD, Mieler WF.
    Journal: Retin Cases Brief Rep; 2008; 2(3):234-5. PubMed ID: 25390096.
    Abstract:
    PURPOSE: To report the changes in intraocular pressure (IOP) after intravitreal injection of bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA). DESIGN: Retrospective chart review. METHODS: After the charts of 29 patients who underwent 51 consecutive intravitreal injections of bevacizumab were reviewed, analysis of the short-term effect of bevacizumab injections on IOP was performed. RESULTS: Mean baseline IOP ± SD was 15.1 ± 2.35 mm Hg (range, 10-22 mm Hg). Mean postinjection IOP ± SD was 20.1 ± 4.70 mm Hg (range, 16-31 mm Hg). Mean change in IOP from baseline to ≈30 minutes after bevacizumab injection was 5.0 mm Hg (P = 0.0027). Mean IOP ± SD at the first follow-up visit, which occurred ≈25 days (range, 5-43 days) after injection, was 14.7 ± 2.93 mm Hg (range, 10-20 mm Hg). CONCLUSIONS: Intravitreal injection of bevacizumab seems to be safe from an IOP standpoint in the short term. IOP monitoring immediately after injection may not be necessary.
    [Abstract] [Full Text] [Related] [New Search]